Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00304187 |
This study will determine the effectiveness of the antibiotic erythromycin in enhancing gastrointestinal function and decreasing the frequency of binge eating in people with bulimia nervosa.
Condition | Intervention | Phase |
---|---|---|
Bulimia Nervosa Eating Disorders |
Drug: Erythromycin Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment |
Official Title: | Effects of Erythromycin on Binge Eating and GI Function in Bulimia Nervosa |
Estimated Enrollment: | 96 |
Study Start Date: | September 2004 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Participants will take erythromycin.
|
Drug: Erythromycin
Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
|
2: Placebo Comparator
Participants will take matched placebo.
|
Drug: Placebo
Placebo, 250 mg or 500 mg, three times a day for 6 weeks
|
Bulimia nervosa (BN) is a serious eating disorder that is characterized by frequent uncontrolled eating binges. These binges are often followed by compensatory behavior, including the following: self-induced vomiting; misuse of laxatives, diuretics, enemas, or other medications to induce purging; fasting; or excessive exercise. If left untreated, BN can lead to many serious health issues: tooth decay; irregular menstruation; bowel damage; constipation; heart and kidney disease; intestinal damage; puffiness, especially in the face and fingers; increased hair growth on the face and body; and mineral imbalances in the body. Although there is significant existing knowledge about the characteristics and treatment of BN, more information is needed about gastrointestinal (GI) function and its effect on binge eating behavior. This study will determine the effectiveness of the antibiotic erythromycin in enhancing GI function and decreasing the frequency of binge eating in people with BN.
Participants in this 8-week, double-blind study will first undergo gastric emptying and GI hormone release testing for 1 day. Within 1 week of completing these pre-treatment tests, participants will be randomly assigned to receive either erythromycin or placebo for 6 weeks. Upon medication assignment, participants will meet with a psychiatrist to receive their assigned medication. Participants will receive medication at weekly study visits. Medication dosage will be increased if symptoms do not improve, or decreased if adverse medication side effects are reported. A final day of gastric emptying and GI hormone release testing, as well as routine blood tests, will take place in Week 7, after 6 weeks of medication treatment. Participants' weight will be measured at Weeks 1, 4, and 7. Participants will also receive an EKG 1 week after each upward dosage adjustment. Patients will be informed of their medication assignment at the Week 7 study visit, and will be referred to a non-study clinician for further treatment.
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Benny J. Chen, BA | 212-543-6248 | edru@pi.cpmc.columbia.edu |
United States, New York | |
Eating Disorders Clinic, New York State Psychiatric Institute | Recruiting |
New York, New York, United States, 10032 | |
Principal Investigator: B. T. Walsh, MD |
Principal Investigator: | B. T. Walsh, MD | New York State Psychiatric Institute at Columbia University Medical Center |
Responsible Party: | The New York State Psychiatric Institute ( B. Timothy Walsh, MD ) |
Study ID Numbers: | R01 MH042206-05, DATR A2-AID |
Study First Received: | March 15, 2006 |
Last Updated: | February 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00304187 |
Health Authority: | United States: Federal Government |
Binge-Eating Disorder |
Erythromycin stearate Signs and Symptoms Bulimia Nervosa Erythromycin Estolate Signs and Symptoms, Digestive Erythromycin Ethylsuccinate |
Mental Disorders Bulimia Erythromycin Eating Disorders Hyperphagia |
Anti-Infective Agents Anti-Bacterial Agents Protein Synthesis Inhibitors Molecular Mechanisms of Pharmacological Action |
Therapeutic Uses Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |